Objective To investigate the effect of anti-Helicobacter pylori (Hp) treatment on blood lipid and inflammation level in patients with coronary heart disease (CHD).
Methods A total of 120 patients with CHD were divided into CHD with Hp negative group (n=48), CHD featured as Hp positive without anti-Hp treatment group (NAHp group, n=32), and CHD featured as Hp positive with anti-Hp treatment group (AHp group, n=40). Among AHp group, the patients were further divided into Hp eradication group (EHp group, n=28) and Hp without eradication group (NEHp group, n=12). All the patients were conducted with routine drug treatment for CHD, including aspirin, atorvastatin and other drugs for secondary prophylaxis, and Hp was treated with 14 d quadruple therapy. The levels of blood lipid and inflammatory markers were measured before treatment and after 4 weeks of treatment in all patients.
Results Before treatment, the levels of total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), oxidized low-density lipoprotein (ox-LDL), C reactive protein (CRP) and homocysteine (Hcy) in the NAHp group and the AHp group were significantly higher than those in the CHD with Hp negative group (P < 0.05); after treatment, the levels of TC, TG, LDL-C, ox-LDL, CRP and Hcy in the EHp group, the NEHp group and the NAHp group decreased significantly when compared to those before treatment (P < 0.05); after 4 weeks of treatment, the levels of TC, TG, LDL-C, ox-LDL, CRP and Hcy in the EHp group were significantly lower than those in the NEHp group (P < 0.05), but the NAHp group showed no significant change in the indexes above (P>0.05).
Conclusion Hp eradication therapy is helpful to improve lipid abnormalities and inflammatory response in patients with CHD, and further optimize the control of risk factors of CHD.
DownLoad: